Daily Biotech Pulse: Clinical Hold Lifted Off Crispr’s Gene-Edited Therapy, Endra To Offer Biedex.coms
Here’s a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
(Biotech stocks hitting 52-week highs on Oct. 10)
- Merck & Co., Inc. (NYSE: MRK)
- Kezar Life Sciences Inc (NASDAQ: KZR)
- RA Medical Systems Inc (NYSE: RMED)
Down In The Dumps
(Biotech stocks hitting 52-week lows on Oct. 10)
- Abeona Therapeutics Inc (NASDAQ: ABEO)
- Achieve Life Sciences Inc (NASDAQ: ACHV)
- Aerpio Pharmaceuticals Inc (NASDAQ: ARPO)
- Aquestive Therapeutics Inc (NASDAQ: AQST)
- Assembly Biosciences Inc (NASDAQ: ASMB)
- Avenue Therapeutics Inc (NASDAQ: ATXI)
- BioSig Technologies Inc (NASDAQ: BSGM)
- BioXcel Therapeutics Inc (NASDAQ: BTAI)
- Capricor Therapeutics Inc (NASDAQ: CAPR)
- Clovis Oncology Inc (NASDAQ: CLVS)
- CytomX Therapeutics Inc (NASDAQ: CTMX)
- CytRx Corporation (NASDAQ: CYTR)
- Erytech Pharma SA (NASDAQ: ERYP)
- Evelo Biosciences Inc NASDAQ: (EVLO)
- Fennec Pharmaceuticals Inc (NASDAQ: FENC)
- Fortress Biotech (NASDAQ: FBIO)
- IntelliPharmaCeutics Intl Inc (NASDAQ: IPCI)
- Iterum Therapeutics PLC (NASDAQ: ITRM)
- Magenta Therapeutics Inc (NASDAQ: MGTA)
- Mersana Therapeutics Inc (NASDAQ: MRSN)
- Miragen Therapeutics Inc (NASDAQ: MGEN)
- MORPHOSYS AG/S ADR (NASDAQ: MOR)
- MoSys Inc. (NASDAQ: MOSY)
- Mustang Bio Inc (NASDAQ: MBIO)
- Neos Therapeutics Inc (NASDAQ: NEOS)
- Novelion Therapeutics Inc (NASDAQ: NVLN)
- Nymox Pharmaceutical Corp (NASDAQ: NYMX)
- Oncolytics Biotech, Inc. (NASDAQ: ONCY)
- Oramed Pharmaceuticals, Inc. (NASDAQ: ORM)
- Pulse Biosciences Inc (NASDAQ: PLSE)
- RXi Pharmaceuticals Corp (NASDAQ: RXII)
- Surface Oncology Inc (NASDAQ: SURF)
- TRACON Pharmaceuticals Inc (NASDAQ: TCON)
- Translate Bio Inc (NASDAQ: TBIO)
- Trevena Inc (NASDAQ: TRVN)
- Unity Biotechnology Inc (NASDAQ: UBX)
- XOMA Corp (NASDAQ: XOMA)
Stocks In Focus
FDA Lifts Clinical Hold On Crispr-Vertex Combine’s Sickle Cell Disease Therapy
Crispr Therapeutics AG (NASDAQ: CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said the FDA has lifted the clinical hold and accepted the investigational new drug application, or IND, for CTX001, their gene-edited hematopoietic stem-cell therapy for treating sickle cell disease, or SCD.
The companies said they have already obtained approvals of Clinical Trial Applications for CTX001 in multiple countries outside the U.S. for both beta-thalassemia and SCD.
The companies also said they remain on track to initiate Phase 1/2 clinical study in SCD by the end of 2018, while they are currently enrolling patients with transfusion-dependent beta-thalassemia in a Phase 1/2 trial in beta-thalassemia in Europe.
Crispr shares jumped 14.14 percent to $41.82 in after-hours trading.
FDA Approves K2M’s Dual Differential Correction Technique
K2M Group Holdings Inc (NASDAQ: KTWO) announced FDA approval as well as surgical guidance that enhances Mesa platform using patient-specific rods and rails. The approval provides for dual differential correction, or DDC, philosophy & technique.
“The DDC philosophy combines rod rigidity and degree of bend with the MESA Platform Technology to help achieve quality outcomes in patients with sagittal imbalance,” the company said.
The stock rallied 4.17 percent to $28.50 in after-hours trading.
Endra To Offer Biedex.coms
ENDRA Life Sciences Inc (NASDAQ: NDRA) said it’s planning to offer common shares in an underwritten public offering. All shares are being offered by the company.
The stock slipped 9.8 percent to $2.30 in after-hours trading.
On The Radar
The Anesthetic and Analgesic Drug Products Advisory Committee of the FDA will discuss Trevena’s NDA for oliceridine 1 milligram/milliliter injection for the management of moderate-to-severe acute pain in adult patients for whom an intravenous opioid is warranted. Following the release of the committee’s briefing document Tuesday, the stock plunged.
Clinical Trial Results
TG Therapeutics Inc (NASDAQ: TGTX) is scheduled to release final Phase 2a data for its relapsing multiple sclerosis treatment candidate TG-1101 at the European Committee for Treatment and Research In Multiple Sclerosis 2018 Congress held in Berlin, Germany.
Allogene Therapeutics, which develops CAR T cell cancer therapies, priced its upized IPO of 18 million shares at $18, at the upper end of the estimated price range of $16-$18. The shares are to be listed on the Nasdaq under the ticker symbol ALLO.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.